PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AGIO vs. ARQT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AGIO and ARQT is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

AGIO vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
-20.19%
45.57%
AGIO
ARQT

Key characteristics

Sharpe Ratio

AGIO:

0.80

ARQT:

1.25

Sortino Ratio

AGIO:

1.55

ARQT:

2.10

Omega Ratio

AGIO:

1.20

ARQT:

1.24

Calmar Ratio

AGIO:

0.58

ARQT:

1.15

Martin Ratio

AGIO:

2.56

ARQT:

4.52

Ulcer Index

AGIO:

18.82%

ARQT:

21.51%

Daily Std Dev

AGIO:

60.63%

ARQT:

77.19%

Max Drawdown

AGIO:

-87.36%

ARQT:

-95.02%

Current Drawdown

AGIO:

-74.81%

ARQT:

-64.58%

Fundamentals

Market Cap

AGIO:

$1.94B

ARQT:

$1.53B

EPS

AGIO:

$11.80

ARQT:

-$1.67

Total Revenue (TTM)

AGIO:

$25.77M

ARQT:

$125.18M

Gross Profit (TTM)

AGIO:

$19.92M

ARQT:

$112.96M

EBITDA (TTM)

AGIO:

-$297.76M

ARQT:

-$109.21M

Returns By Period

In the year-to-date period, AGIO achieves a 3.50% return, which is significantly higher than ARQT's -5.96% return.


AGIO

YTD

3.50%

1M

5.65%

6M

-20.18%

1Y

43.32%

5Y*

-6.83%

10Y*

-10.90%

ARQT

YTD

-5.96%

1M

-10.40%

6M

45.56%

1Y

117.61%

5Y*

-11.99%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AGIO vs. ARQT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGIO
The Risk-Adjusted Performance Rank of AGIO is 7272
Overall Rank
The Sharpe Ratio Rank of AGIO is 7373
Sharpe Ratio Rank
The Sortino Ratio Rank of AGIO is 7272
Sortino Ratio Rank
The Omega Ratio Rank of AGIO is 7171
Omega Ratio Rank
The Calmar Ratio Rank of AGIO is 7070
Calmar Ratio Rank
The Martin Ratio Rank of AGIO is 7171
Martin Ratio Rank

ARQT
The Risk-Adjusted Performance Rank of ARQT is 8181
Overall Rank
The Sharpe Ratio Rank of ARQT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 8282
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 7777
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 8282
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 7979
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AGIO vs. ARQT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AGIO, currently valued at 0.80, compared to the broader market-2.000.002.004.000.801.25
The chart of Sortino ratio for AGIO, currently valued at 1.55, compared to the broader market-4.00-2.000.002.004.006.001.552.10
The chart of Omega ratio for AGIO, currently valued at 1.20, compared to the broader market0.501.001.502.001.201.24
The chart of Calmar ratio for AGIO, currently valued at 0.77, compared to the broader market0.002.004.006.000.771.15
The chart of Martin ratio for AGIO, currently valued at 2.56, compared to the broader market-10.000.0010.0020.002.564.52
AGIO
ARQT

The current AGIO Sharpe Ratio is 0.80, which is lower than the ARQT Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of AGIO and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00SeptemberOctoberNovemberDecember2025February
0.80
1.25
AGIO
ARQT

Dividends

AGIO vs. ARQT - Dividend Comparison

Neither AGIO nor ARQT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AGIO vs. ARQT - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, smaller than the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for AGIO and ARQT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-44.82%
-64.58%
AGIO
ARQT

Volatility

AGIO vs. ARQT - Volatility Comparison

The current volatility for Agios Pharmaceuticals, Inc. (AGIO) is 12.25%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 18.93%. This indicates that AGIO experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
12.25%
18.93%
AGIO
ARQT

Financials

AGIO vs. ARQT - Financials Comparison

This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab